Why the study?
Common neurodegenerative diseases cause progressive neuron damage, and adeno-associated virus-mediated gene therapy offers potential transformative therapies to delay or halt disease progression.
Adeno-associated virus vectors are highlighted as a safe and efficient choice for gene therapy in central nervous system neurodegenerative diseases.
Answers are grounded in this paper and cite their sources.
Supports AAV preference for CNS gene transfer; leaves open optimal applications across neurodegenerative diseases.
Common neurodegenerative diseases of the central nervous system are characterized by progressive damage to the function of neurons, even leading to the permanent loss of function. Gene therapy via gene replacement or gene correction provides the potential for transformative therapies to delay or possibly stop further progression of the neurodegenerative disease in affected patients. Adeno-associated virus has been the vector of choice in recent clinical trials of therapies for neurodegenerative diseases due to its safety and efficiency in mediating gene transfer to the central nervous system. This review aims to discuss and summarize the progress and clinical applications of adeno-associated virus in neurodegenerative disease in central nervous system. Results from some clinical trials and successful cases of central neurodegenerative diseases deserve further study and exploration.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: